Using stem cells to model a heart condition for drug testing
Official title: hiPSC Modeling of Restrictive Cardiomyopathy for Drug Testing
Funded at Stanford University · NIH-10845660 · Data updated 2026-11-12
This study is looking at Restrictive Cardiomyopathy, a heart condition that makes it hard for the heart to fill with blood, and it's using special cells from patients to learn more about the disease and test two new medications that could help, especially for kids who don't have many treatment choices.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $560,399 |
| NIH project number | 5R01HL169340-02 |
| Project ID | NIH-10845660 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Restrictive Cardiomyopathy, particularly those with a genetic predisposition to the condition.
✕Less likely to help
Patients with other forms of cardiomyopathy or those without a genetic basis for their heart condition may not benefit from this research.
What this research studies
This research focuses on Restrictive Cardiomyopathy (RCM), a serious heart condition that primarily affects the heart's ability to relax and fill with blood. By utilizing human induced pluripotent stem cells (hiPSCs) derived from patients, the researchers aim to create models that mimic the disease, allowing them to study its underlying mechanisms and test new drug therapies. The goal is to better understand how specific genetic mutations contribute to RCM and to evaluate the effectiveness of two promising new medications that may improve heart function. This approach is particularly important for pediatric patients, who often face limited treatment options.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with Restrictive Cardiomyopathy, potentially improving their quality of life and outcomes.
How similar studies have gone: While this specific approach using hiPSC models for RCM is novel, similar methodologies have shown promise in other cardiac conditions, indicating potential for success.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: Mercola, Mark — Stanford University
- Study coordinator: Mercola, Mark
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.